Acrivon Therapeutics
ACRV
46 hedge funds and large institutions have $38.1M invested in Acrivon Therapeutics in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 4 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
69% more capital invested
Capital invested by funds: $22.6M → $38.1M (+$15.5M)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
8.1% more ownership
Funds ownership: 41.91% → 50% (+8.1%)
5% more funds holding
Funds holding: 44 → 46 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$6.61M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$542K |
| 3 |
Two Sigma Investments
New York
|
+$428K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$391K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$280K |
| 2 |
Morgan Stanley
New York
|
-$53.4K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$48.5K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$47K |
| 5 |
Squarepoint
New York
|
-$24.1K |
ACRV Hedge Fund Activity: Q2 2026 in Review
46 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q2 2026, worth a combined $38.1M — up 69% from $22.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ACRV positions and 4 closed out — a net gain of 2 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was RA Capital Management, adding an estimated $6.61M. The largest seller was Jane Street, cutting an estimated $280K.
- 46 institutional investors held Acrivon Therapeutics (ACRV) as of Q2 2026, up from 44 in Q1 2026.
- Funds reported $38.1M of Acrivon Therapeutics stock for Q2 2026, up 69% quarter-over-quarter.
- 6 funds opened new Acrivon Therapeutics positions in Q2 2026 and 4 closed out, a net change of +2 holders.
- The largest Acrivon Therapeutics buyer in Q2 2026 was RA Capital Management, an estimated $6.61M added.
- The largest Acrivon Therapeutics seller in Q2 2026 was Jane Street, an estimated $280K sold.
Based on aggregated 13F filings for Q2 2026.